[{"id":"beb344ab-95cf-420e-8ccd-b61bc4f7a537","acronym":"","url":"https://clinicaltrials.gov/study/NCT07097363","created_at":"2025-08-02T14:05:17.045Z","updated_at":"2025-08-02T14:05:17.045Z","phase":"Phase 2","brief_title":"Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT07097363","lead_sponsor":"University of Washington","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 05/31/2030","primary_completion_date":" 05/31/2030","study_txt":" Completion: 05/31/2030","study_completion_date":" 05/31/2030","last_update_posted":"2025-07-31"},{"id":"27333119-b7fd-424a-9cb7-3d186e837736","acronym":"","url":"https://clinicaltrials.gov/study/NCT06965114","created_at":"2025-06-14T13:57:06.110Z","updated_at":"2025-06-14T13:57:06.110Z","phase":"Phase 1/2","brief_title":"Study for Patients With Hairy Cell Leukemia to Test the Targeted Agent Tovorafenib in Combination With Rituximab and Compare the Combination With Current Standard Treatment","source_id_and_acronym":"NCT06965114","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cladribine • Ojemda (tovorafenib) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 09/30/2025","start_date":" 09/30/2025","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2025-06-11"},{"id":"a4247f5e-b84a-4f2b-a095-1fca8e76f331","acronym":"","url":"https://clinicaltrials.gov/study/NCT06905509","created_at":"2025-08-02T14:06:01.421Z","updated_at":"2025-08-02T14:06:01.421Z","phase":"Phase 2","brief_title":"Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","source_id_and_acronym":"NCT06905509","lead_sponsor":"University of California, Davis","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 08/01/2030","study_completion_date":" 08/01/2030","last_update_posted":"2025-04-01"},{"id":"d1651a97-e0b7-453b-880d-d4d563121330","acronym":"","url":"https://clinicaltrials.gov/study/NCT06834373","created_at":"2025-02-25T13:57:53.594Z","updated_at":"2025-02-25T13:57:53.594Z","phase":"Phase 2","brief_title":"Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy","source_id_and_acronym":"NCT06834373","lead_sponsor":"Mayo Clinic","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar) • golcadomide (CC-99282)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 03/03/2025","start_date":" 03/03/2025","primary_txt":" Primary completion: 03/03/2027","primary_completion_date":" 03/03/2027","study_txt":" Completion: 03/03/2027","study_completion_date":" 03/03/2027","last_update_posted":"2025-02-20"},{"id":"da3b2b09-ed01-4312-97c2-dda82f0fd6ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT04799275","created_at":"2021-03-16T18:52:53.431Z","updated_at":"2025-02-25T13:53:42.140Z","phase":"Phase 2/3","brief_title":"Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT04799275","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BCL6 • CD4","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Onureg (azacitidine oral) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 422","initiation":"Initiation: 05/20/2021","start_date":" 05/20/2021","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2025-02-20"},{"id":"e2ff7fb5-f1de-4b7f-9fd4-438675875b61","acronym":"","url":"https://clinicaltrials.gov/study/NCT02160015","created_at":"2021-01-18T10:03:19.018Z","updated_at":"2025-02-25T13:52:04.076Z","phase":"Phase 1","brief_title":"Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02160015","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD4 • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD20 • CD4 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 05/20/2014","start_date":" 05/20/2014","primary_txt":" Primary completion: 03/27/2017","primary_completion_date":" 03/27/2017","study_txt":" Completion: 08/13/2025","study_completion_date":" 08/13/2025","last_update_posted":"2025-02-20"},{"id":"61d56240-acd7-4036-be44-40ad727ab77a","acronym":"A051701","url":"https://clinicaltrials.gov/study/NCT03984448","created_at":"2021-01-18T19:35:47.901Z","updated_at":"2025-02-25T15:11:12.787Z","phase":"Phase 2/3","brief_title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","source_id_and_acronym":"NCT03984448 - A051701","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" BCL2 expression • MYC expression • MYC translocation • MYC negative • BCL2 translocation","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • MYC translocation • MYC negative • BCL2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 363","initiation":"Initiation: 10/22/2019","start_date":" 10/22/2019","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2025-02-13"},{"id":"f18181fc-ba3a-410b-9369-091830924976","acronym":"","url":"https://clinicaltrials.gov/study/NCT05457556","created_at":"2022-09-07T16:55:34.255Z","updated_at":"2025-02-25T15:12:56.234Z","phase":"Phase 3","brief_title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT05457556","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • methotrexate • melphalan • Truxima (rituximab-abbs) • fludarabine IV • thiotepa • busulfan • Mabtas (rituximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 435","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-13"},{"id":"53b3407a-20b5-4273-98e0-b8684d9dff01","acronym":"","url":"https://clinicaltrials.gov/study/NCT01829568","created_at":"2021-01-18T08:08:01.489Z","updated_at":"2025-02-25T14:34:07.166Z","phase":"Phase 1","brief_title":"Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma","source_id_and_acronym":"NCT01829568","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD4","pipe":"","alterations":" ","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 06/26/2013","start_date":" 06/26/2013","primary_txt":" Primary completion: 05/11/2015","primary_completion_date":" 05/11/2015","study_txt":" Completion: 01/24/2026","study_completion_date":" 01/24/2026","last_update_posted":"2025-02-10"},{"id":"302e12e8-3d06-4205-8871-3fc4c45bd55f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01856192","created_at":"2021-01-18T08:17:29.922Z","updated_at":"2025-02-25T16:43:43.231Z","phase":"Phase 2","brief_title":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT01856192","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • MYC • CD20 • CD4","pipe":" | ","alterations":" CD20 expression • MYC translocation","tags":["ALK • MYC • CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression • MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 349","initiation":"Initiation: 08/27/2013","start_date":" 08/27/2013","primary_txt":" Primary completion: 03/26/2020","primary_completion_date":" 03/26/2020","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"3e01dea9-3971-4487-84c5-6452884a557d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00972478","created_at":"2021-01-18T03:47:26.597Z","updated_at":"2025-02-25T16:36:04.200Z","phase":"Phase 1/2","brief_title":"Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT00972478","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Zolinza (vorinostat) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 11/15/2010","start_date":" 11/15/2010","primary_txt":" Primary completion: 12/30/2015","primary_completion_date":" 12/30/2015","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-06"},{"id":"9bf88391-bf8e-4bd2-b27f-b745a3c4ca24","acronym":"ECOG-ACRIN E1910","url":"https://clinicaltrials.gov/study/NCT02003222","created_at":"2021-01-18T09:08:51.217Z","updated_at":"2025-02-25T16:36:18.435Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02003222 - ECOG-ACRIN E1910","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CDKN2A • RUNX1 • IGH • ETV6 • CD4 • TCF3 • PBX1","pipe":"","alterations":" ","tags":["ABL1 • BCR • CDKN2A • RUNX1 • IGH • ETV6 • CD4 • TCF3 • PBX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • cyclophosphamide • Blincyto (blinatumomab) • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • Truxima (rituximab-abbs) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 488","initiation":"Initiation: 05/19/2014","start_date":" 05/19/2014","primary_txt":" Primary completion: 06/23/2023","primary_completion_date":" 06/23/2023","study_txt":" Completion: 03/14/2025","study_completion_date":" 03/14/2025","last_update_posted":"2025-02-06"},{"id":"b4947302-8201-4385-90e7-1045ddc21de5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03220022","created_at":"2021-01-18T15:53:27.752Z","updated_at":"2025-02-25T17:29:32.862Z","phase":"Phase 1","brief_title":"Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas","source_id_and_acronym":"NCT03220022","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD4","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Udenyca (pegfilgrastim-cbqv) • Ziextenzo (pegfilgrastim-bmez) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 03/16/2018","start_date":" 03/16/2018","primary_txt":" Primary completion: 06/20/2025","primary_completion_date":" 06/20/2025","study_txt":" Completion: 06/20/2025","study_completion_date":" 06/20/2025","last_update_posted":"2025-01-30"},{"id":"65f11ba4-54ff-43fd-a6f2-54316429b85b","acronym":"ECOG-ACRIN E1912","url":"https://clinicaltrials.gov/study/NCT02048813","created_at":"2021-01-17T17:35:11.745Z","updated_at":"2024-07-02T16:34:37.153Z","phase":"Phase 3","brief_title":"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT02048813 - ECOG-ACRIN E1912","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CCND1 • IGH • CD4 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14) • CD4 positive","tags":["CD20 • CCND1 • IGH • CD4 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CD4 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • cyclophosphamide • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 529","initiation":"Initiation: 02/20/2014","start_date":" 02/20/2014","primary_txt":" Primary completion: 10/24/2018","primary_completion_date":" 10/24/2018","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-07"},{"id":"8de268c6-da6c-4e99-84fd-668feff0456e","acronym":"ALLIANCE A041202","url":"https://clinicaltrials.gov/study/NCT01886872","created_at":"2021-01-17T17:18:59.159Z","updated_at":"2024-07-02T16:34:37.292Z","phase":"Phase 3","brief_title":"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT01886872 - ALLIANCE A041202","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD4 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD20 • CD4 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine • Truxima (rituximab-abbs) • Belrapzo (bendamustine RTD) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 547","initiation":"Initiation: 12/09/2013","start_date":" 12/09/2013","primary_txt":" Primary completion: 08/07/2018","primary_completion_date":" 08/07/2018","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2024-06-07"},{"id":"01dd1666-57b1-4023-ba76-ce9718bafa53","acronym":"NCI-2017-01957","url":"https://clinicaltrials.gov/study/NCT03321643","created_at":"2021-01-18T16:24:29.884Z","updated_at":"2024-07-02T16:34:58.900Z","phase":"Phase 1","brief_title":"Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT03321643 - NCI-2017-01957","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • gemcitabine • Rituxan (rituximab) • oxaliplatin • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 09/18/2018","start_date":" 09/18/2018","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-04"},{"id":"18ee0f81-3adf-4bd7-8334-4d0c4101af0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05886036","created_at":"2023-11-15T20:15:29.821Z","updated_at":"2024-07-02T16:35:07.221Z","phase":"Phase 2","brief_title":"Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma","source_id_and_acronym":"NCT05886036","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • PD-1 • PD-L2","pipe":" | ","alterations":" CD20 expression","tags":["CD20 • PD-1 • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Lunsumio (mosunetuzumab-axgb) • Mabtas (rituximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 01/23/2024","start_date":" 01/23/2024","primary_txt":" Primary completion: 10/31/2026","primary_completion_date":" 10/31/2026","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2024-04-29"},{"id":"ec361a88-10be-462e-b8c7-8fa193d6a067","acronym":"","url":"https://clinicaltrials.gov/study/NCT03418038","created_at":"2021-01-18T16:51:47.082Z","updated_at":"2024-07-02T16:35:11.929Z","phase":"Phase 2","brief_title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","source_id_and_acronym":"NCT03418038","lead_sponsor":"Mayo Clinic","biomarkers":" IDH1 • BCL2 • IDH2 • DNMT3A • SF3B1 • TET2 • SRSF2 • U2AF1 • CD4 • ZRSR2","pipe":" | ","alterations":" IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation","tags":["IDH1 • BCL2 • IDH2 • DNMT3A • SF3B1 • TET2 • SRSF2 • U2AF1 • CD4 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 03/23/2018","start_date":" 03/23/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-02"},{"id":"d0d47c61-61e0-4557-9a9c-103d7e9e6b56","acronym":"","url":"https://clinicaltrials.gov/study/NCT01695941","created_at":"2021-01-29T07:03:45.178Z","updated_at":"2024-07-02T16:35:15.783Z","phase":"Phase 1","brief_title":"Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT01695941","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bortezomib • alisertib (MLN8237) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 08/31/2012","start_date":" 08/31/2012","primary_txt":" Primary completion: 05/29/2018","primary_completion_date":" 05/29/2018","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2024-03-07"},{"id":"26065744-c262-4f87-91b1-e6294c2cfbc7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04323956","created_at":"2021-01-18T20:56:54.236Z","updated_at":"2024-07-02T16:35:31.265Z","phase":"Phase 1","brief_title":"Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT04323956","lead_sponsor":"Mayo Clinic","biomarkers":" MYC • BCL2 • CD20 • BCL6","pipe":" | ","alterations":" BCL2 expression • MYC expression • CD20 expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • CD20 expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • parsaclisib (INCB50465) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/15/2020","start_date":" 06/15/2020","primary_txt":" Primary completion: 05/15/2026","primary_completion_date":" 05/15/2026","study_txt":" Completion: 05/15/2027","study_completion_date":" 05/15/2027","last_update_posted":"2023-10-30"}]